Compound Detail
CHEMBL1200788
CISAPRIDE MONOHYDRATE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL1200788 |
| Name | CISAPRIDE MONOHYDRATE |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | QBYYXIDJOFZORM-UHFFFAOYSA-N |
| Parent Compound | CHEMBL1729 |
| Active Moiety | CHEMBL1729 |
2
Targets
2
Activities
1
Assay Types
1
PK Parameters
8
Publications
6
Known Names
1
Mechanisms
Molecular Properties
465.9
MW (Da)
3.36
ALogP
6
HBA
2
HBD
86.0
PSA (Ų)
0.44
QED
0
Ro5 Violations
9
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 1993 |
| Availability | Withdrawn |
| Chirality | Racemic |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Serotonin 4 (5-HT4) receptor agonist | AGONIST | 5-hydroxytryptamine receptor 4 | ✓ | ✓ |
Drug Warnings
Withdrawn
cardiotoxicity
Serious cardiac arrhythmias (e.g. ventricular tachycardia, torsades de pointes, and ventricular fibrillation) and sudden cardiac deaths
Withdrawn
cardiotoxicity
Rare but serious cardiac adverse effects; Adverse cardiac events published by the FDA.; Serious cardiovascular adverse effects
Withdrawn
cardiotoxicity
Serious cardiac arrhythmias (e.g. ventricular tachycardia, torsades de pointes, and ventricular fibrillation) and sudden cardiac deaths
Withdrawn
General Warning
Documented reports on adverse events including deaths associated with its use; Rare but serious heart complications including arrhythmias and sudden death
Withdrawn
cardiotoxicity
Fatal arrhythmia
Withdrawn
cardiotoxicity
Association with cardiac arrhythmias and a number of deaths
Withdrawn
General Warning
Association with cardiac arrhythmias and a number of deaths
Withdrawn
cardiotoxicity
Serious cardiovascular adverse effects
Withdrawn
cardiotoxicity
Possibility of rare but serious heart complications including arrhythmias and sudden death; Rare but serious heart complications including arrhythmias and sudden death; Increased risk of cardiac arrhy...
Withdrawn
cardiotoxicity
Reports about cardiac arrhythmias with highest strength cisapride
Activity Summary
IC50 2 meas. best 7.4
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Voltage-gated inwardly rectifying potassium channel KCNH2 CHEMBL240 | IC50 | 7.4 | 7.4 | 40.0 | 1 |
| Bile salt export pump CHEMBL6020 | IC50 | 4.66 | 4.66 | 22000.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| AUC | 2226.78 | ng.hr.mL-1 | Homo sapiens |
Activity Data Samples
Top measurements by pChEMBL value
| Target | Type | Rel. | Value | Units | pChEMBL | Assay | PubMed |
|---|---|---|---|---|---|---|---|
| Voltage-gated inwardly rectifying potassium channel KCNH2 | IC50 | = | 40.0 | nM | 7.4 | Inhibition of hERG potassium channel assessed as maximum inhibition rate at -80 ... | 34080858 |
| Bile salt export pump | IC50 | = | 22000.0 | nM | 4.66 | Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as... | 23956101 |
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 23956101 | 10.1093/toxsci/kft176 | Homo sapiens | 2 |
| 34080858 | 10.1021/acs.jmedchem.1c00621 | Voltage-gated inwardly rectifying potassium channel KCNH2 | 2 |
| 23956101 | 10.1093/toxsci/kft176 | Bile salt export pump | 1 |
| 23956101 | 10.1093/toxsci/kft176 | ATP-binding cassette sub-family C member 2 | 1 |
| 23956101 | 10.1093/toxsci/kft176 | ATP-binding cassette sub-family C member 3 | 1 |
| 23956101 | 10.1093/toxsci/kft176 | ATP-binding cassette sub-family C member 4 | 1 |
| 23956101 | 10.1093/toxsci/kft176 | Unchecked | 1 |
| - | 10.6019/EOS300108 | HepG2 | 1 |
Data from ChEMBL 36 via Core Engine